Selank
Selank (TP-7); Thr-Lys-Pro-Arg-Pro-Gly-Pro heptapeptide; tuftsin analog with C-terminal Pro-Gly-Pro extension
Not FDA-approved. Not on the FDA Category 2 list (only the parent compound Semax is listed). Approved in Russia as an anxiolytic.
A synthetic peptide developed and used clinically in Russia for reducing anxiety and supporting cognitive function. It works by calming the brain's natural relaxation system and preserving mood-regulating brain chemicals. It is not approved by the US FDA or European regulators.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
Safety Summary
Selank is generally well tolerated with minimal adverse effects. No serious adverse events, dose-limiting toxicities, dependence, tolerance, or withdrawal phenomena have been documented in human trials or preclinical studies. The Medvedev et al. 2015 study (PMID:26356395) found that adding selank to phenazepam actually decreased undesirable benzodiazepine side effects (attention/memory impairment, asthenia, sedation, sexual disturbances). No evidence of carcinogenicity in preclinical studies. Embryonic stem cell toxicity testing showed selank produced no toxic effect during embryonic/fetal period (PMID:29063333).
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Sources: [1-14]